newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

- SLS-009 is Seelos' First Internally Created Program - Seelos is also evaluating SLS-009 in two preclinical in vivo studies in Amyotrophic Lateral Sclerosis and Alzheimer's Disease NEW YORK, May 5, 2023